In a recent study, Pignatelli et al. [107] have shown a reduction in NOX2 activity and H2O2 levels in diabetic patients after 15 days of treatment with SGLT2-i; furthermore, the use of SGLT2-i has demonstrated the improvement in platelet function through the reduction in thromboxane, soluble P-selectin, and soluble CD40 ligand levels, suggesting a further mechanism that takes action in preventing the progression of ATS. This evidence concerns the gene SLC5A2 and Andersen-Tawil syndrome.